Lumbab, Baby Boy .

HRN: 21-57-45  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/02/2022
AMPICILLIN 250MG (VIAL)
08/02/2022
08/09/2022
IV
75mg
Q12hours
PSNB
Waiting Final Action 
08/02/2022
GENTAMICIN 40MG/ML, 2ML (AMP)
08/02/2022
08/08/2022
IV
7mg
OD
PSNB
Waiting Final Action 
08/22/2022
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
08/22/2022
08/28/2022
IVT
15mg As LD Then 8mg
OD
Sepsis
Waiting Final Action 
08/22/2022
CEFOTAXIME 500MG (VIAL)
08/22/2022
08/28/2022
IVT
42mg
Q8
Sepsis
Waiting Final Action 
08/22/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/22/2022
08/28/2022
IVT
18mg
OD
Sepsis
Waiting Final Action 
08/27/2022
CEFTAZIDIME 1GM (VIAL)
08/27/2022
09/03/2022
IV
36 Mg
Q8H
Sepsis Neonatorum
Waiting Final Action 
08/27/2022
OXACILLIN 500MG (VIAL)
08/27/2022
09/03/2022
IV
60 Mg
Q6H
Sepsis Neonatorum
Waiting Final Action 
08/27/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/27/2022
09/03/2022
IV
18 Mg As LD Then 9mg
Q12H
Sepsis Neonatorum
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: